Drugmaker Accused of Overhyping Proposed COVID Treatment Agrees to $3M Settlement

"Plaintiffs assert that lenzilumab's prospects of success were overstated, that defendants failed to disclose material adverse nonpublic information concerning the scientific merits of repurposing lenzilumab as a COVID treatment as part of a scheme to mislead investors into purchasing shares of Humanigen stock," U.S. District Judge William J. Martini said.

September 16, 2024 at 03:13 PM

4 minute read

Colleen Murphy